1 year ago

179

https://patents.justia.com/patent/20150250725

https://pubchem.ncbi.nlm.nih.gov/patent/WO-2018078053-A1

Leadership Team - CureVac
curevac.com/en/about-us/leadership-team
CureVac Swiss AG. Basel, Switzerland Wartenbergstraße 40 CH-4052 Basel T +49 7071 9883 - 0 F +49 7071 9883 - 1101. CureVac RNA Printer GmbH. Tübingen, Germany
https://www.curevac.com/en/about-us/leadership-team/

Leadership Team - CureVac
https://www.curevac.com/en/about-us/leadership-team
Previously, Viola was Head of Communications of Roche Diagnostics GmbH and of Roche Diagnostics Europe, Middle East, Africa, and before that, of Lilly Pharma Holding GmbH. ... CureVac AG. Frankfurt, Germany Clinical development …
https://www.curevac.com/en/about-us/leadership-team/

CureVac Collaboration | Bill & Melinda Gates Foundation
gatesfoundation.org/Ideas/Media-Center/Press-Releases/2015/03/CureVac...
SEATTLE, WA, USA and TÜBINGEN, GERMANY (March 5, 2015) – The Bill & Melinda Gates Foundation and CureVac today announced that the foundation has made a
https://www.gatesfoundation.org/Ideas/Media-Center/Press-Releases/2015/03/CureVac-Collaboration

https://sif.gatesfoundation.org/investments/curevac/
https://edition.cnn.com/2020/08/17/investing/curevac-vaccine-stock/index.html

https://endpts.com/biontech-partners-with-bill-and-melinda-gates-foundation-scoring-55m-equity-investment-novartis-sells-china-unit/

Foundation Medicine's Tie Ups With Roche, Bill Gates And Google ...
seekingalpha.com/article/4017652
Bill Gates and Google ( GOOG) ( GOOGL) Ventures are also owners in this genomic testing company. However, right now, the stock is trading at $22.50, about half that Roche https://seekingalpha.com/article/4017652-foundation-medicines-tie-ups-roche-bill-gates-and-google-ventures-are-major-value-drivers

Acuitas Therapeutics – Backgrounder
acuitastx.com/wp-content/uploads/2020/12/Acuitas-Backgrounder.pdf
Acuitas Therapeutics – Backgrounder Founded in February 2009, Vancouver-based Acuitas Therapeutics is a private biotechnology company that specializes in the development of
https://acuitastx.com/wp-content/uploads/2020/12/Acuitas-Backgrounder.pdf

all branched off from Arbutus Biopharma Corp
https://www.rfemerge.com/2021/05/02/the-mrna-ip-and-competitive-landscape-translate-bio-arcturus-etherna-and-other-startups-and-lnp-technology-part-ii/

Board of Directors | Arbutus Biopharma Corporation
arbutusbio.gcs-web.com/board-directors
He formerly served as Chief Financial Officer for the Bill & Melinda Gates Foundation with responsibility for finance and accounting, financial planning and analysis, strategic
https://arbutusbio.gcs-web.com/board-directors

formerly Tekmira Pharmaceuticals Corporation
Arbutus Biopharma Corporation | BIOTECHNOLOGY REPORT
biotechnology.report/companies/arbutus-biopharma-corporation
Arbutus Biopharma Corporation (formerly Tekmira Pharmaceuticals Corporation) is a publicly-traded (NASDAQ:ABUS) biopharmaceutical company dedicated to discovering,
https://biotechnology.report/companies/arbutus-biopharma-corporation

Roche Partners with Tekmira Pharmaceuticals to Advance RNAi Product ...
investor.arbutusbio.com/news-releases/news-release-details/roche-partners...
Vancouver, BC — Tekmira Pharmaceuticals Corporation (TSX: TKM) announced today that it has entered into a product development agreement with global healthcare company
https://investor.arbutusbio.com/news-releases/news-release-details/roche-partners-tekmira-pharmaceuticals-advance-rnai-product

I think that the wef's, of which Roche is no small part, chinese side of the crimes against humanity patnership has been pretty well covered already hasnt it

https://www.science.org/content/blog-post/mrna-s-history--and-its-future

The tumultuous price wars of the 1970's were not the only source of difficulties for the company. In 1976 a poison cloud of TCDD, a dioxin found in AGENT ORANGE, escaped from Icmesa, an Italian chemical factory owned by Hoffmann-La Roche.

Oh, and this is what you can find in today's death vax bioweapon
Hoffmann-La Roche has also been at the forefront of genetic engineering, particularly in its production of interferons. Roferon-A, released on the market in June of 1986, is marketed as a treatment for rare forms of cancer.
Bell's Palsy in COVID-19 Vaccine Trials: What You Need To Know
verywellhealth.com/bells-palsy-covid-19-5093172
Reports released from Pfizer and Moderna show that seven COVID-19 vaccine trial participants experienced a type of facial paralysis, called Bell's palsy, in the weeks after vaccination. This rare side effect, in tandem with three reports of severe allergic reactions,
https://www.verywellhealth.com/bells-palsy-covid-19-5093172

WHY i SHOULDNT WORRY???????? YOU GOTTA FACE MADE FOR RADIO ANYWAY SON. THANKS
Pathological consequences of excess of interferon in vivo
researchgate.net/publication/332559413_Pathological_consequences_of_excess...
In the experiments to be presented herein, it was found that small amounts of sheep antimouse interferon globulin (AIF) 1 rendered genetically resistant mice fully susceptible to the lethal effect ...
BABY MICE
When Ion Gresser and his collaborators reported their experiences of a toxic effect of interferon type 1 in newborn mice, the communityScientific scientist, at the time, did not measure this discovery at its true value and sometimes even, some wanted to see it only as an artifact

strains of mice when administered in high doses [13]. In particular, after injection of interferon highly purified, newborn mice develop a syndrome characterized by growth arrest, necrosis of the liver and death, between one to two weeks of life
GREAT

https://www.researchgate.net/publication/332559413_Pathological_consequences_of_excess_of_interferon_in_vivo
Disease-Promoting Effects of Type I Interferons in Viral, Bacterial ...
ncbi.nlm.nih.gov/pmc/articles/PMC4389918
Detrimental effects can be due to the suppression of antibacterial responses (IL-1, IL-17, IFN-γ, and KC) or to overstimulation of inflammation leading to damage by apoptosis of
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4389918/

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7897359/

Hoffmann-La Roche has also been at the forefront of genetic engineering, particularly in its production of interferons. Roferon-A, released on the market in June of 1986, is marketed as a treatment for rare forms of cancer.

Loading comments...